Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Flohr

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
British Journal of Cancer|January 28, 2010
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancerA H M Reid, G Attard, L Ambroisine, et al.
Prostate Cancer and Prostatic Diseases|February 24, 2010
The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancerL Shan, L Ambroisine, J Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2017
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repairT R Shenoy, G Boysen, M Y Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancerM P Kolinsky, P Rescigno, D Bianchini, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
British Journal of Cancer|January 28, 2010
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancerA H M Reid, G Attard, L Ambroisine, et al.
Prostate Cancer and Prostatic Diseases|February 24, 2010
The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancerL Shan, L Ambroisine, J Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2017
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repairT R Shenoy, G Boysen, M Y Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancerM P Kolinsky, P Rescigno, D Bianchini, et al.
Pageof 3